Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Egetis, FDA Approval

By Inderes9/29/2026, 6:00 AM
Egetis Therapeutics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Nicklas Westerholm
00:01 - 04:06

Thank you very much. Operator, thank you, everyone, for joining us today. For those who haven't had the privilege to meet before, my name is Nicklas Westerholm and I'm the CEO of Egetis Therapeutics. Today is a truly historic and transformative day for Egetis Therapeutics with the approval of EMCITATE for patients with MCT8 deficiency in the United States. Joining me today is our Chief Medical Officer, Tiago Nunes, who will remind us about the severe condition of MCT8 deficiency. We also have Christian Sonesson, Vice President, Product Strategy and Development, who will elaborate on our robust data package that formed the basis of the NDA and the USPI, the so-called label. Last but not least, we have Anny Bedard, President of Egetis Therapeutics in North America, who will elaborate on our launch readiness. Next slide, please. We will also leave ample time for questions and answers at the end. So late last night, we announced that the US Food and Drug Administration has approved EMCITATE for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency. This approval represents the first and only FDA-approved treatment for this rare, severe, life-shortening genetic disorder and marks an important milestone for patients, families, clinicians, and the broader community affected by this condition. The journey to diagnosis and care is often difficult and uncertain. Today changes that. For Egetis Therapeutics, this approval represents far more than a regulatory milestone. It is the culmination of a comprehensive development program that has evaluated EMCITATE across multiple clinical studies and patient populations. It is a validation of years of research and development, together with our key collaborator, the Erasmus Medical Center, or EMC, from Rotterdam. This also marks the beginning of a new chapter for us as a company, as we transition fully into a commercial-stage rare disease company in the world's largest pharmaceutical market. So our focus now turns from approval to commercialization. We have been preparing for this moment and have established a commercial and medical affairs infrastructure necessary to support patients and healthcare providers from day one. Our goal is simple: to help eligible patients gain access to EMCITATE as quickly and seamlessly as possible following approval. We are also pleased that the FDA granted a Rare Pediatric Disease Priority Review Voucher in connection with the approval. The voucher represents a very important financial asset for the company and will provide additional flexibility as we continue to execute our mid- to long-term growth strategy, building a sustainable rare disease company. As outlined in today's press release, we expect to evaluate opportunities for the monetization of the voucher during the fourth quarter of this year. Today's achievement also reinforces the strength of Egetis Therapeutics' rare disease strategy. We remain focused on developing and commercializing therapies that address significant unmet medical needs for small patient populations, where meaningful innovation can have a profound impact on patients' lives. With that, I will now hand over the call to our Chief Medical Officer. Tiago Nunes, who will discuss the devastating condition of MCT8 deficiency.

Tiago Nunes
04:06 - 07:53

Thank you. Nicklas. MCT8 deficiency is a rare, severely debilitating, life-shortening condition. It is caused by mutations in the SLC16A2 gene located on the X chromosome, hence its predominance in males. MCT8 deficiency-impaired transport of thyroid hormone leads to low T3 levels in the brain and high circulating T3 levels. This disease is characterized by impairment in neurodevelopment and systemic metabolic and cardiovascular disturbances with increased morbidity and mortality. There is a median overall survival of 35 years of age, and it is expected that 1 in 3 children with MCT8 deficiency will not survive to adulthood. Cellular differences inMr. MCT8 dependence leads to simultaneous thyroid hormone insufficiency in the CNS, central nervous system, and persistent peripheral thyrotoxicosis. This is a clinical state in which tissues are exposed to and respond to excessive thyroid hormone. Thyroid hormone insufficiency in the central nervous system occurs because T3 cannot enter due to MCT8 dysfunction. MCT8 dysfunction. Entry of T3 via alternative transporters leads to peripheral thyrotoxicosis. In the periphery, organs like the heart and the muscle are affected. In MCT8 deficiency, clinical presentation results from thyroid hormone insufficiency in the central nervous system and persistent peripheral thyrotoxicosis. These patients present high T3 levels, the active hormone; low to normal T4 levels, the storage hormone; and TSH, which is the control hormone, that is normal or slightly elevated. SLC16A2 genetic testing confirms the diagnosis. Impairment in neurodevelopment, hypotonia, and failure to thrive are characteristic. Untreated. Persistent. Peripheral thyrotoxicosis. The main symptoms include tachycardia. Cardiac arrhythmias and hypertension are associated with an elevated risk of major cardiovascular events and cardiovascular abnormalities. Sudden death has been reported as a frequent cause of mortality and is likely linked to underlying cardiac abnormalities. The treatment of MCT8 deficiency is multidisciplinary, and one of the main focuses of treatment is the management of failure to thrive. Most affected patients are underweight, with body weight for age showing a progressive decline over time. Undernourishment can weaken the immune system, leading to difficulties fighting infections. Failure to gain weight is associated with poor prognosis and increased risk of death in this population. Until recently, there was no approved drug for the management of MCT8 deficiency. The approval of EMCITATE for the treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency has changed that. EMCITATE is a thyroid hormone receptor agonist that enters MCT8-dependent cells independently of the MCT8 transporter. EMCITATE replaces T3 in MCT8-dependent tissues and normalizes thyroid hormone activity across tissues. Clinical trials show that EMCITATE reduces serum T3 levels and improves clinical manifestations of thyrotoxicosis, which are associated with increased morbidity and cardiovascular mortality. I now want to introduce Christian Sonesson, Vice President, Product Strategy and Development. To take a closer look at the clinical data supporting EMCITATE treatment in MCT8 deficiency.

Christian Sonesson
07:54 - 14:33

Thank you Tiago. Um, next slide please. So before I turn to the label itself, let me start with the clinical evidence submitted in the NDA. This package rests on two pillars. First, three clinical studies, Triac Trial I, which established the core effect of EMCITATE in lowering T3 and improving the clinical markers of thyrotoxicosis. ReTRIACt, the randomized withdrawal study, delivered confirmatory placebo-controlled evidence that this T3-lowering effect is directly attributable to EMCITATE, and Triac Trial II, which added safety data at higher doses in the youngest patients, together with three independent sources of real-world evidence, the Erasmus Medical Center cohort study, followed patients for up to six years, confirming that the effect on T3 and clinical markers of thyrotoxicosis are durable over the long term. The EMC Survival study, which examined treated versus untreated patients in a cohort of more than 600 individuals, and the U.S. Expanded Access program showed that the real-world experience in the U.S. was consistent with everything we had seen in the clinical trials. From this clinical package, really two things stand out. First, the robustness of the data behind EMCITATE, which is unusually complete for an ultra-rare genetic disease. And second, the consistency of the results across different designs, different populations, and different settings. And building on what you heard Tiago just described, the biological plausibility of the treatment effects seen in our clinical data has been key in the NDA package. Thyrotoxicosis is a well-characterized condition. It is linked to cardiovascular and metabolic harm, which is extensively documented, and correcting the thyroid hormone excess is known to reverse it. With EMCITATE lowering the elevated T3, we see the expected clinical benefits also in patients with MCT8 deficiency. So the clinical data in the NDA package do not stand alone. They sit on top of well-established biology. Every piece of data we have moved in the same direction, and that coherence is what underpins our confidence in the clinical package. Next slide please. So, turning to the label itself. Key here is the broad indication statement covering all patients with MCT8 deficiency, saying that EMCITATE is a thyroid hormone receptor agonist indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency. With this approval, EMCITATE becomes the first and only approved therapy for these patients in the United States. The remainder of this slide gives a brief overview of the highlights of the USPI. The class black box warning, how the medicine is dosed and individualized. The dosage forms, the warnings, and precautions. The contraindications. The most common adverse reactions and drug interactions. I won't go through each of these in detail here. The full approved prescribing information is the definitive source, and it is linked on this slide for anyone who would like to see the complete safety and usage information. Next slide please. Here we see how the clinical data package translates into section 14 of the USPI. In other words, which studies the FDA considered adequate and well-controlled to provide the primary support of effectiveness. Two studies are included. ReTRIACt is. ReTRIACt is the randomized withdrawal study. It gives us two findings. First, the rate of T3 change, where total T3 rose 1.5 times faster on placebo than on EMCITATE during the randomized treatment period, with a p-value of 0.034. Second, the need for rescue, where four out of eight patients on placebo met the rescue criterion of total T3 above the upper limit of normal versus one out of seven on EMCITATE. I would note the asterisks here that that single case was a participant who discontinued prematurely for reasons not related to the drug, and was counted as having met the criteria. What is also worth emphasizing is the consistency. Every patient randomized to placebo had a larger increase in total T3 than any participant who continued on EMCITATE. EMCITATE. Triac Trial I. Triac Trial I is study two. A 12-month open-label study where we saw a reduction in mean total T3 from 323 to 118 nanograms per deciliter over a year, a change of -205, with a p-value below 0.0001. Alongside that, key clinical markers of thyrotoxicosis improved: systolic blood pressure down, heart rate down, and body weight-for-age z-score up. All three secondary endpoints moved in the direction of reduced peripheral thyrotoxicosis, which is positive to have acknowledged in labeling. Given the importance of improvement of thyrotoxicosis in this patient population, as previously covered by Christian Sonesson. The EMCITATE survival study was not included in labeling. It's important to remember that this study is a retrospective, real-world cohort study, and the scientific and regulatory perspective on rigor is slightly different. And ultimately, the FDA considered that, given the limitations of the retrospective, real-world design, the study did not meet the regulatory requirements for an adequate and well-controlled study. But certainly, from a scientific perspective, we are confident that the EMC-survival study is unprecedented, and the data have been shown to be robust across a multitude of different sensitivity analyses. Instead, in the short term, we look forward to seeing the EMCITATE survival study published so that the scientific and clinical community can be informed about the study. With that, I hand over to Anny Bedard, our President of North America, to cover the U.S. launch readiness.

Anny Bedard
14:35 - 21:41

Thank you very much, Christian. Today marks an important milestone for the MCT8 deficiency community and for Egetis Therapeutics. EMCITATE is the first and only approved treatment in the United States, and for Egetis Therapeutics, this is a significant achievement. It marks our transition from a development-stage company to a commercial rare disease organization. This is a pivotal moment, with our focus now shifting to execution, enabling access, and supporting physicians and families through treatment initiation. Next slide please. Our commercial readiness is grounded in real-world experience, extensive pre-approval preparation, and stakeholder insight. We identified more than 100 genetically confirmed patients, of which more than 60 have been treated with EMCITATE across 17 sites in our Early Access program. Evidence of an identified patient base. We have confidence in the therapeutic effectiveness. Early adoption and physician motivation. Motivation to prescribe. Following approval, our work with patient advocacy organizations has raised the patient voice, built disease awareness, and shaped the caregiver experience. Education and support are rolling out at launch. The community is informed and ready to act, which we expect will translate into faster identification and referral of patients. We engaged payers well ahead of approval, including the three largest pharmacy benefit managers, representing more than 80% of U.S. prescription claims and more than a third of state Medicaid plans. Feedback has been constructive, with payers recognizing the burden of the disease and the importance of appropriate access for eligible patients. We are confident in the team we have built. Their rare disease expertise, multi-launch experience, and disciplined execution give us conviction in our ability to deliver. Next slide. More than 65% of early access patients are managed across six centers, which gives us a concentrated place to start. Supporting. Continuity of care is our top priority. Our team is prepared to work with physicians and, where they determine continued treatment is appropriate, help patients transition from Early Access to commercial supply. The same preparation applies to the remaining early access sites. Every investigator and care team has been engaged multiple times by our medical team ahead of approval, and account-level activation plans are ready to go. Next slide. Persistent peripheral thyrotoxicosis is a central feature of MCT8 deficiency and is associated with systemic burden, medical fragility, and increased mortality risk. Until now, no approved treatment has been available. The price of EMCITATE balances four principles: access, affordability, the value of the medicine, and sustaining innovation. It reflects the severity and life-shortening nature of MCT8 deficiency. The absence of approved alternatives. Potential to address the modifiable systemic driver of morbidity and mortality, and the need to reliably supply and support an ultra-rare patient population. We've set the wholesale acquisition cost at $74,026 per pack of 60 tablets of 350 micrograms, based on the average daily dose of approximately 740 micrograms observed in Triac Trial I and as described in the U.S. Prescribing Information. This equates to an annualized wholesale acquisition cost of approximately 950,000 USD. Broad and equitable access remains our commitment, and our work with payers will continue through launch and beyond. This gives Egetis Therapeutics a strong foundation for commercialization and sustainable growth. Next slide. To support access to therapy, we built Egetis RareLink, a fit-for-purpose patient support program developed in partnership with PANTHERx Rare Pharmacy. Egetis RareLink brings treatment, education, access, support, and specialty pharmacy coordination into one connected experience. The program offers personalized support through a patient support liaison, dedicated care managers who help coordinate insurance requirements, financial support options, and resources for families and providers. Our goal is to help families and providers move through the access process efficiently. Next slide. Commercial product is expected to be available in approximately 8 to 10 weeks. In the meantime, prescription enrollment and access preparation begin now through Egetis RareLink. We will support physicians through that process so the necessary steps are completed before product availability, allowing eligible patients to move toward treatment efficiently once supply is available. And as stated, this is an exciting and defining moment for the patients, for the MCT8 deficiency community and for Egetis Therapeutics. So from here, it's execution, discipline, delivery, appropriate patient access, and establishing EMCITATE as the standard of care for peripheral thyrotoxicosis in MCT8 deficiency. And we are ready. With that, I'll turn it back to Nick.

Nicklas Westerholm
21:42 - 23:56

Thank you very much, Anny. And let me now close on how we see the value drivers for the company. EMCITATE addresses a devastating rare disease with severe life-long morbidity, shortening life expectancy and causing a substantial caregiver burden. It is now the first and only approved therapy in the United States for patients with MCT8 deficiency, following the EU approval in February last year. This truly marks the transition for Egetis Therapeutics into a fully commercial-stage rare disease company. As you have heard from Anny, we're ready to launch in the U.S., the world's largest pharmaceutical market. Around 60 US patients are already on expanded access, with more than 100 identified. The patient pool continues to grow. We see the EMCITATE clinical profile and disease severity supporting orphan premium pricing and exclusivity. We have seven years of orphan drug exclusivity in the U.S., ten years in Europe and Japan, with patents expected to provide protection until roughly 2045. Furthermore, we see that indication expansion into RTHβ represents a meaningful additional growth opportunity in a larger, non-overlapping patient population with cardiovascular morbidity, where the ambition is to start a pivotal study next year. Last but not least, I would like to acknowledge and thank the people who made this achievement possible. We are deeply grateful to the patients, caregivers, investigators, clinicians, and advocacy organizations whose partnership and determination made this achievement possible. Finally, I would like to thank everyone at Egetis Therapeutics. This approval reflects years of dedication, persistence, and unwavering focus on our mission to bring innovative therapies to patients with rare diseases. So with that, thank you. We are now happy to take questions. Operator, over to you.

Operator
23:57 - 24:10

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. The next question comes from Kristen Kluska from Cantor Fitzgerald. Please go ahead.

Kristen Kluska
24:12 - 24:47

Hi, everybody. Good morning and congratulations on this approval. You should be very proud of all the work you've done for this rare disease community. So, I have a few questions. First, how should we be thinking about gross-to-net pricing? And then second, I know you mentioned that there were over 100 patients identified in the U.S. I believe when you really first started this mission, there were far fewer patients that you had identified in the U.S. Hello? Hello?

Unknown 1
24:50 - 24:51

Yes, we can hear you.

Kristen Kluska
24:51 - 24:52

Hello.

Anny Bedard
24:52 - 24:55

We can hear you, Kristen. Yes, we can.

Kristen Kluska
24:55 - 25:04

Oh, okay. Perfect. Okay. Good morning. Congratulations on this approval. You should feel very proud of all the work you've done here. You should be proud of your work for this patient community.

Unknown 1
25:05 - 25:06

Yeah. Everything is working.

Kristen Kluska
25:09 - 25:14

Okay, great. I have just two questions. First, how should we be thinking about the gross-to-net pricing?

Unknown 1
25:14 - 25:14

Sort.

Kristen Kluska
25:14 - 25:36

Of gross-to-net pricing. And then second, of the identified pool of 100-plus patients, do you believe that this number has grown substantially since you started working in the U.S.? Can you give us a sense of the most successful ways you have been able to identify these patients and how you plan to use that going forward to further grow that pool?

Unknown 2
25:40 - 25:41

So I think that.

Anny Bedard
25:47 - 25:49

Nick, would you like me to take that answer?

Unknown 3
25:50 - 25:51

If you go out.

Anny Bedard
25:57 - 25:58

Can you hear me, Christian?

Unknown 1
25:58 - 26:01

We seem to have a problem with the speaker line. They are logging on again.

Kristen Kluska
26:01 - 26:03

Yes, I can hear you.

Unknown 1
26:04 - 26:07

This is. Yes, it is logging on. So now they're back again.

Nicklas Westerholm
26:07 - 26:08

Can anybody hear us?

Unknown 1
26:08 - 26:09

Yes.

Anny Bedard
26:09 - 26:10

I can hear you.

Unknown 1
26:12 - 26:40

We can hear you, Nicklas. Maybe I can help. I can try and dial out from the system to call, and we can continue on the phone if they have problems with the internet in the room, or if you can try to reconnect. Maybe you can start, Anny.

Anny Bedard
26:40 - 27:47

Yes, I will answer that. Apologies for those technical challenges. So in terms of the gross-to-net, at this moment, we are not giving any specific guidance regarding the gross-to-net, but we do expect it to reflect the payer mix that we have. And that does include a meaningful proportion of Medicaid patients, which includes in our assumption the customary government rebates, discounts, and also other channel deductions that we are taking into consideration. But I guess here the question comes really mostly based on the high proportion of pediatric patients that we have. And hence, a significant number of patients that will include government rebates. So that's the information that we can share at this moment; we will continue to monitor that as well as we refine the information that we get into our exact payer mix.

Nicklas Westerholm
27:48 - 28:12

I apologize. We are back from the Stockholm office. We seem to have some technology issues. Thank you for responding to the question, which we did not hear. But Kristin, thank you all for your acknowledgement of the progress we have made so far. And I hope and assume that you got answers to the two questions you posed, which again, we didn't have an opportunity to hear the second.

Anny Bedard
28:12 - 29:31

The first question was regarding our expectations on gross-to-net. And the second question was regarding the number of patients that we have achieved in terms of identifying to date, what has been most successful, and how we can continue to use that moving forward. So we've been using multiple approaches to help identify patients prior to our teams being all on board. Conferences were one of the key initiatives where patients have been identified, and since we have built our team and have been actively present, that has contributed significantly to increasing the number of new patients identified as we increase awareness. We are also leveraging other mechanisms such as data analytics. And looking at building some algorithms that can help us better identify patients in populations that have characteristics looking similar to MCT8 deficiency. So we've been using different channels. And we will continue to leverage these. Most of them have been very effective.

Nicklas Westerholm
29:32 - 30:11

Thank you, Anny and Kristin. I know we discussed this before, but I'm sure you appreciate that, as with many rare diseases where you haven't had an approved therapy, patient identification usually starts to rapidly evolve post-approval. The estimated incidence levels in this disease, roughly 1 in 70,000 males, are born with this condition when you account for a median life expectancy. And considering the US population, you are looking at a patient population of roughly 1,000 in the US. Thank you, Anny, for managing this. And I think we should now move to the next question.

Operator
30:14 - 30:19

The next question comes from Chiara Montironi from Van Lanschot Kempen. Please go ahead.

Tim Olsen
30:22 - 30:58

Good morning, team. Congratulations on the fantastic update. I have a couple of questions. So the first one will be to make sure that the label also includes infants and that there is not a cutoff for age. And then, I was wondering, in terms of funding, do you believe you can fully cover the launch and also a potential registrational trial for RTHβ. RTHβ. Given this pricing and the PRV.

Nicklas Westerholm
31:01 - 32:44

Thank you. Tim Olsen, great questions as always, let us be very, very clear here. There are no age restrictions whatsoever in the label. Very important. The FDA approval gives us eligibility to treat all patients with MCT8 deficiency regardless of age. So I think that is very, very important and on par with the label we see in the European Union. The second question was around RTHβ, cash, runway, etc. . Monetization of the PRV is of course very important for us. That is something we will progress now in the fourth quarter. I am sure you appreciate that 50% of the net proceeds is eligible for the company. You are seeing that the latest sales prices of a PRV during 2026 have been in the range of 180 million to 220 million USD per voucher. So obviously, this adds an incredibly important financial flexibility and will most definitely support the upcoming launch during 2026 until the company becomes cash positive. When it comes to RTHβ, it is difficult to give you a straight answer there now because it is still a work in progress. Our Chief Medical Officer, sitting next to me here on my right-hand side, is working very diligently on finalizing the clinical trial design for a pivotal study. So I am sure you appreciate that until the study design has been finalized, including sample size, it is difficult to cost that. So we have to get back to the market on that specific topic. But thank you very much for your questions. Operator. Next question, please.

Tim Olsen
32:44 - 32:45

Thank you.

Nicklas Westerholm
32:45 - 32:46

Oh, sorry.

Operator
32:46 - 32:49

The next question comes from Clemens Troy from Stifel. Please go ahead.

Clemens Troy
32:51 - 33:41

Hi, Tim. First, congratulations on the approval. And thanks for taking our question. So, just following up from some of the earlier questions. So I understand you are working hard to turn the existing patient pool into commercial patients as quickly as possible. And with your 60 patients receiving therapy through the EAP, how quickly do you think those patients can transition onto commercial EMCITATE? And how should we think about the timing of bringing the other treatment-naive patients onto therapy? That would be the first and the second on reimbursement. You've obviously been engaging with commercial payers and Medicare. Is there anything that you can share on the feedback you received so far and how you are thinking about access and coverage in the early post-launch period? Thank you very much.

Nicklas Westerholm
33:41 - 34:24

Thank you very much. I will provide a couple of overview remarks on this. And then I'll hand over to Anny. But I think you're absolutely right that the 60 patients on EAP is the highest priority short term to ensure continuity of care. Very important, of course, to ensure that, but also to realize revenue sooner rather than later. So with that, Anny, I don't know if you want to provide some more granularity on the transition of EAP patients into commercial product, as well as how we view the additional patient pool of identified patients and their transition to commercial product. Anny, over to you.

Anny Bedard
34:25 - 36:01

Yeah. Thank you. Absolutely. I want to reemphasize that the continuity of care is our top priority and we have been preparing very well for that transition. And we've been engaging, as I mentioned earlier, extensively with all the sites to facilitate this transition. We will be working with the physicians and with caregivers through our Egetis RareLink in order to make sure that all these families are ready. In terms of access and until the product is available, in terms of the speed of getting access, we expect that this will be a progressive uptake. Typically, we know that in general, for a rare disease launch, it may take 6 to 12 months for coverage policies to be fully established. However, in the meantime, we will work with each patient case by case through our support with the Egetis RareLink in order to provide them access. So that is how we are planning to operate in terms of the patients that were not part of the EAP program. This will follow a similar process to get them access as quickly as possible.

Nicklas Westerholm
36:03 - 36:27

Thank you, Anny. I would like to again reiterate the unmet medical need here. You heard from Tiago about the devastating condition with the shortened median life expectancy. So I think the sense of urgency is there, both from physicians but also caregivers. Thank you so much, Christian. And I think we will move to the last question of today from Arvid.

Operator
36:28 - 36:33

The next question comes from Arvid Necander from ABG Sundal Collier. Please go ahead.

Arvid Necander
36:35 - 37:35

Good morning, everyone, and congratulations. Congratulations on this great milestone today. So, I have a question on the claims you can now make and the pricing implications. I guess overall this seems like a really clean label and broadly in line with what we saw in Europe. Just wondering how you expect the lack of mortality claims to influence pricing here? And do you believe that the analogs you have put forward in the past are still relevant? And I guess more broadly, within that sort of range that the analogs provide us with, have you gained more confidence on where it should be in that pricing interval now that you know which claims you can make? It would be interesting to hear your thoughts here. And then just a quick last one, if I may. You said a little bit about the payer mix and that there will be a meaningful part in the Medicaid population. Roughly what is the split between commercial and Medicare/Medicaid here? Thanks.

Nicklas Westerholm
37:36 - 38:57

Thank you, Arvid, and good questions. As always, let's start with the price. As I assume you heard from this call from Anny, we have set the wholesale acquisition cost at $74,026 per pack. There are 60 tablets per pack. That translates into an annualized wholesale acquisition cost of approximately $950,000 per patient per annum. So that's the price we have set. It is very important to recognize that when it comes to the other components, we truly believe that this is an orphan premium price even without the mortality data in the label. And we also see that moving forward, as Christian mentioned, we're very much looking forward to the EMCITATE survival study being published and for the medical community to fully appreciate what's in that study. But I'll hand over to Anny to further elaborate on the label, if she has any comments. But again, re-emphasizing that there are no restrictions on the label from an age perspective, and all patients with MCT8 deficiency should be eligible. Any over to you.

Anny Bedard
38:58 - 39:36

Yeah. In terms of the pricing, I think you have captured everything. As it relates to your second question about the Medicaid and Medicare split right now, we are looking at a disease that is much more pediatric. So we expect that we will get a significantly larger proportion of Medicaid patients. The exact split is still going to be refined as we learn more about the patients who start therapy, but definitely a greater proportion of Medicaid patients.

Arvid Necander
39:39 - 40:00

Great. Thanks for that. Just a final follow-up, if I may. Sorry, I was a bit late to the call, so I didn't get the gross pricing number, but that's very transparent. It's just. Is there anything leading you to believe that the discounting would not be within the typical 20 to 30% gross-to-net discounting range? Can you comment further on that?

Nicklas Westerholm
40:01 - 40:16

No. I think it is reasonable to believe that the part of the payer mix that is related to Medicaid will have the usual rebates, around 23%. When it comes to commercial payers, we don't see any discount whatsoever.

Arvid Necander
40:19 - 40:23

Great. That is very helpful. Thank you so much. And congratulations again.

Nicklas Westerholm
40:23 - 40:46

Thank you so much. Thank you, everybody for participating today. We apologize for the technical issues we experienced on our end during the initial part of the question and answer session. But again, today truly marks a historical moment for Egetis Therapeutics and patients with MCT8 deficiency in the US. I wish you all a great rest of the day. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…